Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2016-11-03 |
NBE Therapeutics (Switzerland) |
CHF 20 million (€ 18.5 million) |
series B financing round |
PPF Group (Czech Republic) Boehringer Ingelheim Venture Fund (BIVF) (Germany) existing private investors and a new private investor |
|
Series B financing round |
2016-10-25 |
eHealth Ventures (Israel) |
|
financing round |
Amgen (USA - CA) Maccabi Healthcare Services (Israel) Medison Pharma (Israel) |
|
Financing round |
2016-10-18 |
Mavalon Therapeutics (UK) |
up to € 9 million |
financing round |
Medicxi Ventures (UK - Switzerland) |
Neurodegenerative diseases |
Financing round |
2016-10-12 |
Immunomedics (USA - NJ) |
$30 million |
private placement |
|
Cancer - Oncology |
Private placement |
2016-10-07 |
Newron Pharmaceuticals (Italy) |
CHF 26.1 million (€ 23.9 million) |
private placement |
|
CNS diseases |
Private placement |
2016-10-06 |
Genfit (France) |
€ 33.9 million |
private placement |
|
Metabolic diseases - Liver diseases - Hepatic diseases |
Private placement |
2016-10-06 |
PDC*line Pharma (France) |
€4 million |
financing round, loan, grant |
Meusinvest (Belgium) Spinventure (Belgium) the Financière Spin-off Luxembourgeoise/INVESTSUD Group (Belgium), international business angels including Serge Goblet (Tolefi), Baudouin Jolly, Françoise Jolly-de Vaucleroy, Parness SA, Jean-Paul Prieels (former senior vice president of R&D at GSK Vaccines) and Riccardo Cortese (former CEO of Okairos and current CEO of Nouscom) |
Cancer - Oncology |
Fundraising |
2016-10-05 |
Scynexis (USA - NJ) |
$ 15 million |
loan |
Solar Capital (USA - CA) |
Infectious diseases |
Loan |
2016-10-05 |
Probiodrug (Germany) |
€ 14.9 million |
capital increase |
|
Neurodegenerative diseases |
Capital increase |
2016-10-04 |
SkylineDx (USA - CA - The Netherlands) Erasmus MC (The Netherlands) Myeloma Patients Europe (Belgium), University of Turin (Italy) the Institute for Medical Technology Assessment (The Netherlands) |
multi-million € |
grant |
European Commission’s Horizon 2020 programme |
Cancer - Oncology - Diagnostic |
Grant |
2016-10-04 |
Oxford Immunotec (UK) |
$40 million (€35.7 million) |
credit line and loan |
Midcap Financial (USA - MD) |
Diagnostic |
Loan |
2016-10-04 |
NewLink Genetics (USA - IO) |
$24.8 million |
grant |
Biomedical Advanced Research and Development Authority (USA) |
Infectious diseases |
Grant |
2016-10-03 |
Carrick Therapeutics (Ireland) |
$95 million (€84.7 million) |
financing round |
ARCH Venture Partners (USA - IL) Cambridge Enterprise Seed Funds (UK) Cambridge Innovation Capital (UK) Evotec (Germany) Google Ventures (USA - CA) Lightstone Ventures (USA - CA) Woodford Investment Management (UK) |
Cancer - Oncology |
Financing round |
2016-10-03 |
Array BioPharma (USA - CO) |
$132.25 million (€ 117.9 million) |
private placement |
|
Cancer - Oncology |
Private placement |
2016-10-03 |
Array BioPharma (USA - CO) |
$132.25 million |
private placement |
|
Cancer - Oncology |
Private placement |
2016-10-03 |
Emmaus Life Sciences (USA) |
$20 million |
private placement |
KPM Tech (Republic of Korea) Hanil Vacuum (Republic of Korea) |
Rare diseases - Gastrointestinal diseases |
Private placement |
2016-09-30 |
Onxeo (France) |
€12.5 million |
capital increase |
|
Cancer - Oncology - Rare diseases |
Capital increase |
2016-09-26 |
Oryzon Genomics (Spain) |
€ 10.5 million + € 5.3 million |
loan |
undisclosed Spanish commercial banks |
Cancer - Oncology - Neurodegenerative diseases |
Loan |
2016-09-23 |
Sarepta Therapeutics (USA - MA) |
up to $225 million |
private placement |
|
Rare diseases - Genetic diseases |
Private placement |
2016-09-23 |
AC Immune (Switzerland) |
$57.8 million |
IPO |
|
Neurological diseases - CNS diseases |
IPO |